Seasonal influenza virus vaccine trivalent - Omninvest

Drug Profile

Seasonal influenza virus vaccine trivalent - Omninvest

Alternative Names: FAB 3511; FAB 6011; FAB 9011; FLUVAL AB; FLUVAL K; Intransal seasonal influenza virus vaccine - Omninvest; Low-dose seasonal influenza virus vaccine trivalent - Omninvest; Nazoflu; Trivalent seasonal influenza virus vaccine - Omninvest

Latest Information Update: 17 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Omninvest
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 17 Jan 2017 No development reported - Phase-III for Influenza virus infections (In adolescents, In children, Prevention) in Hungary (IM)
  • 15 Oct 2014 Phase-III clinical trials in Influenza virus infections (Prevention, In children, In adolescents) in Hungary (IM)
  • 07 Feb 2014 No development reported - Registered for Influenza virus infections in Hungary (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top